Apertura signs multiple licensing agreements for TfR1 CapX tech
The deals were signed with Galibra Neuroscience and Emugen Therapeutics, alongside a biotech company.
Cytiva Pipe dream to pipeline WP 3
Japan MHLW approves Biostar’s angel stem cell therapy for autism
Prasad’s FDA exit may accelerate cell and gene therapy approvals
Sarepta Therapeutics to cut 500 jobs amid restructuring
Ultragenyx receives complete response letter for UX111 BLA
Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies
Harbour BioMed partners Otsuka on new T-cell therapy
NSW government invests $13.39m in life-changing therapies
